The zebrafish has become a widely used model organism due to its high fecundity, morphological and physiological similarity to mammals, availability of genomic tools, and the ease of performing large-scale phenotype-based screens. These attributes make it a promising tool for accelerating drug discovery. By combining the scale and throughput of in vitro screens with the physiological complexity of animal studies, the zebrafish can contribute to various aspects of drug development, including target identification, disease modeling, lead discovery, and toxicology. The zebrafish genome has been sequenced, and numerous genetic screens have been conducted, leading to the identification of thousands of mutations affecting organogenesis, physiology, and behavior. These mutations provide valuable insights into gene function and disease mechanisms. Genetic and morpholino oligonucleotide screens are efficient methods for systematically assessing gene roles in disease processes and identifying novel drug targets. Zebrafish models have been used to study various diseases, including polycystic kidney disease, cholesterol processing, tissue regeneration, heart disease, anemias, and cancer. These models recapitulate human disease states and have led to the discovery of new human disease genes. Zebrafish also offer a powerful platform for phenotype-based drug discovery, where compounds that modify disease phenotypes can be identified without knowing the specific molecular target. Phenotype-based screens in zebrafish can identify compounds that suppress genetic defects, such as those in the gridlock and crb mutants. These screens are highly efficient and can be performed on a large scale, making them cost-effective and suitable for high-throughput screening. Zebrafish are also valuable for toxicology studies, as they allow for the assessment of compound safety in a physiologically relevant context. Zebrafish toxicity assays can predict drug failures before clinical trials, reducing development costs. The zebrafish offers advantages over conventional in vitro approaches, including the ability to address biological questions that cannot be addressed in vitro and the potential for more relevant results. Zebrafish screens can identify compounds that are effective in whole organisms, even if they do not act on the same molecular targets as in vitro screens. While zebrafish may not perfectly model human disease, they show a high degree of similarity in drug responses, making them a valuable tool for drug discovery and development. Overall, the zebrafish is a promising model organism for drug discovery, offering a cost-effective, efficient, and physiologically relevant alternative to traditional mammalian models. Its ability to perform large-scale screens, identify novel drug targets, and assess compound safety makes it an important asset in the development of new therapies.The zebrafish has become a widely used model organism due to its high fecundity, morphological and physiological similarity to mammals, availability of genomic tools, and the ease of performing large-scale phenotype-based screens. These attributes make it a promising tool for accelerating drug discovery. By combining the scale and throughput of in vitro screens with the physiological complexity of animal studies, the zebrafish can contribute to various aspects of drug development, including target identification, disease modeling, lead discovery, and toxicology. The zebrafish genome has been sequenced, and numerous genetic screens have been conducted, leading to the identification of thousands of mutations affecting organogenesis, physiology, and behavior. These mutations provide valuable insights into gene function and disease mechanisms. Genetic and morpholino oligonucleotide screens are efficient methods for systematically assessing gene roles in disease processes and identifying novel drug targets. Zebrafish models have been used to study various diseases, including polycystic kidney disease, cholesterol processing, tissue regeneration, heart disease, anemias, and cancer. These models recapitulate human disease states and have led to the discovery of new human disease genes. Zebrafish also offer a powerful platform for phenotype-based drug discovery, where compounds that modify disease phenotypes can be identified without knowing the specific molecular target. Phenotype-based screens in zebrafish can identify compounds that suppress genetic defects, such as those in the gridlock and crb mutants. These screens are highly efficient and can be performed on a large scale, making them cost-effective and suitable for high-throughput screening. Zebrafish are also valuable for toxicology studies, as they allow for the assessment of compound safety in a physiologically relevant context. Zebrafish toxicity assays can predict drug failures before clinical trials, reducing development costs. The zebrafish offers advantages over conventional in vitro approaches, including the ability to address biological questions that cannot be addressed in vitro and the potential for more relevant results. Zebrafish screens can identify compounds that are effective in whole organisms, even if they do not act on the same molecular targets as in vitro screens. While zebrafish may not perfectly model human disease, they show a high degree of similarity in drug responses, making them a valuable tool for drug discovery and development. Overall, the zebrafish is a promising model organism for drug discovery, offering a cost-effective, efficient, and physiologically relevant alternative to traditional mammalian models. Its ability to perform large-scale screens, identify novel drug targets, and assess compound safety makes it an important asset in the development of new therapies.